Central Texas TX

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Brenham Banner Press

Mar 22, 2021

AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human…

Read the full story at Brenham Banner Press

Related places

Brenham Austin

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Related places

More from Central Texas

Dozens of Shiba Inus parade through Pease Park

2 years into Austin's I-35 overhaul, here's what's coming next

POLL: Do you prefer voting early or on Election Day?

Amber Alert issued for missing 15-year-old girl from Copperas Cove

Buda marks 25 years of economic development with larger than life wiener dog sculpture

U.S. Army pilot asks Austin to help find his hat after it fell from helicopter

Buda marks 25 years of economic development with larger than life weiner dog sculpture

Ink Masters in town for the weekend